Table 1.
Demographic and clinical characteristics of patients
| Sample status | AJCC stage (18) | No. of samples, (%) | Training set, No. | Validation set, No. | Sex |
Median age (range), y | Median BMIa, kg/m2 | |
|---|---|---|---|---|---|---|---|---|
| Male | Female | |||||||
| PC | Total | 347 (56.8) | 232 | 115 | 231 | 116 | 66.0 (29-99) | 21.9 |
| IA | 7 (1.1) | 5 | 2 | 5 | 2 | 65.0 (55-77) | 20.1 | |
| IB | 6 (1.0) | 4 | 2 | 3 | 3 | 70.0 (56-79) | 24.5 | |
| IIA | 18 (2.9) | 12 | 6 | 10 | 8 | 66.0 (44-80) | 22.7 | |
| IIB | 80 (13.1) | 53 | 27 | 55 | 25 | 65.0 (47-86) | 22.6 | |
| Early-stage PC (IA, IB, IIA, IIB) | 111 (18.2) | 74 | 37 | 73 | 38 | 65.0 (44-86) | 22.7 | |
| III | 13 (2.1) | 9 | 4 | 9 | 4 | 67.5 (52-78) | 21.2 | |
| IV | 27 (4.4) | 18 | 9 | 21 | 6 | 64.0 (47-80) | 22.3 | |
| Unknown | 196 (32.1) | 131 | 65 | 128 | 68 | 69.0 (29-99) | 21.7 | |
| Diabetes | NA | 55 (9.0) | 37 | 18 | 31 | 24 | 55.0 (39-72) | 24.7 |
| Normal | NA | 209b (34.2) | 133 | 66 | 113 | 96 | 36.0 (18-73) | 23.1 |
a
For BMI, 1 out of 27 in PC stage IV, 13 out of 196 in PC with unknown stage, and 16 out of 209 in normal were excluded for data unavailability. AJCC = American Joint Committee on Cancer; BMI = body mass index; NA = not applicable; PC = pancreatic cancer.
b
Among 209 normal samples, 199 samples were analyzed for asprosin, 207 samples were analyzed for CA19-9, and 197 samples were analyzed for both asprosin and CA19-9 combined. Training and validation set measurements were performed only for asprosin.